FluWatch report: January 26 to February 1, 2020 (week 05)
Download the alternative format
(PDF format, 737 KB, 13 pages)
Organization: Public Health Agency of Canada
Date published: 2020-02-07
- Influenza activity remained high in week 05, with almost all indicators increasing from the previous week.
- Influenza A and B continue to co-circulate.
- Influenza A(H1N1) is currently the dominant influenza A circulating in Canada, representing 84% of subtyped influenza A specimens in week 05.
- The highest cumulative hospitalization rates are among children under 5 years of age and adults 65 years of age and older.
On this page
- Influenza/ILI Activity (geographic spread)
- Laboratory Confirmed Influenza Detections
- Syndromic/Influenza-like Illness Surveillance
- Influenza Outbreak Surveillance
- Severe Outcomes Influenza Surveillance
- Influenza Strain Characterizations
- Antiviral Resistance
- Vaccine Monitoring
- Provincial and International Influenza Reports
Influenza/Influenza-like Illness (ILI) Activity (geographic spread)
During week 05, influenza activity was reported in all provinces and territories and in almost all regions (51). Among these regions, 56% reported sporadic activity, 38% reported localized activity, and 4% reported widespread activity (Figure 1).
Figure 1 – Map of influenza/ILI activity by province and territory, Canada, week 2020-05
Number of Regions Reporting in Week 05: 52 out of 53
Figure 1 - Text equivalent
|Province||Influenza Surveillance Region||Activity Level|
|P.E.I.||Prince Edward Island||Sporadic|
|N.S.||Zone 1 - Western||Sporadic|
|N.S.||Zone 2 - Northern||Sporadic|
|N.S.||Zone 3 - Eastern||Sporadic|
|N.S.||Zone 4 - Central||Sporadic|
|Que.||Québec et Chaudieres-Appalaches||Sporadic|
|Que.||Montréal et Laval||Sporadic|
Laboratory-Confirmed Influenza Detections
In week 05, the percentage of laboratory tests positive for influenza continued to increase and surpassed the previous peak reported in late December. The percentage of tests positive for influenza was 30% in week 05, up from 28% in week 04. Influenza A and B continue to co-circulate; however, the recent increase in laboratory detections is mainly driven by an increase in influenza B detections.
The following results were reported from sentinel laboratories across Canada (Figures 2 and 3):
- The percentage of tests positive for influenza B was 14% week 05. This continues to be three times greater than the average (4.2%) for this time of year.
- The percentage of tests positive for influenza A was 16% in week 05, which is average for this time of year.
- Among subtyped influenza A detections, influenza A(H1N1) accounted for 84% of detections, up from 75% in week 04.
To date this season (weeks 35 to 05), 29,023 laboratory detections of influenza were reported:
- 58% (16,763) were influenza A.
- Among subtyped influenza A detections (4,470), A(H1N1) is the predominant subtype this season (61%).
Detailed information on age and type/subtype has been received for 20,036 laboratory-confirmed influenza cases (Table 1). To date this season (weeks 35 to 05):
- Among cases of influenza A(H3N2) (1,524), the largest proportion were in adults 65 years of age and older (47%).
- Cases of influenza B (8,993) were primarily in younger age groups; 55% of cases were under 20 years of age and 32% between 20 and 44 years of age.
- Among cases of influenza A(H1N1) (1,934), 31% of cases were in adults 65 years of age and older, with approximately equal proportions in adults 20-44 years and 45-64 years (~25%).
For more detailed weekly and cumulative influenza data, see the text descriptions for Figures 2 and 3 or the Respiratory Virus Detections in Canada Report.
Figure 2 - Number of positive influenza tests and percentage of tests positive, by type, subtype and report week, Canada, weeks 2019-35 to 2020-05
Number of Laboratories Reporting in Week 05: 34 out of 36
The shaded area indicates weeks where the positivity rate was at least 5% and a minimum of 15 positive tests were observed, signalling the period of seasonal influenza activity.
Figure 2 - Text equivalent
|Surveillance Week||A(Unsubtyped)||A(H3N2)||A(H1N1)pdm09||Influenza B||Percent Positive A||Percent Positive B|
Figure 3 – Distribution of positive influenza specimens by type/subtype and province/territoryFootnote *, Canada, weeks 2019-35 to 2020-05
- Footnote *
Specimens from NWT, YT, and Nvt are sent to reference laboratories in other provinces.
Figure 3 - Text equivalent
|ProvincesTable Figure 3 - Footnote 1||Cumulative (August 25, 2019 to February 1, 2020)|
|A Total||A(H1N1)||A(H3N2)||A(UnS)Table Figure 3 - Footnote 3||B Total||A & B Total|
|PercentageTable Figure 3 - Footnote 2||58%||16%||10%||70%||42%||100%|
|Cumulative (August 25, 2019 to February 1, 2020)|
|Influenza A||B||Influenza A and B|
|A Total||A(H1N1)||A(H3N2)||A (Un subtyped)Table 1 Footnote 1||Total||#||%|
Syndromic / Influenza-like Illness Surveillance
Healthcare Professionals Sentinel Syndromic Surveillance
In week 05, 1.6% of visits to healthcare professionals were due to influenza-like illness (ILI) which is below the average for this time of year (Figure 4).
Figure 4 – Percentage of visits for ILI reported by sentinels by report week, Canada, weeks 2019-35 to 2020-05
Number of Sentinels Reporting in Week 05: 90
The shaded area represents the maximum and minimum percentage of visits for ILI reported by week from seasons 2014-2015 to 2018-2019
Figure 4 - Text equivalent
The proportion of FluWatchers participants reporting symptoms of cough and fever increased in week 05 compared to the previous week. In week 05, 3,165 participants reported to FluWatchers, of which 3.4% (109) reported symptoms of cough and fever (Figure 5).
Among the 109 participants who reported cough and fever:
- 20% consulted a healthcare professional;
- 74% reported days missed from work or school, resulting in a combined total of 250 missed days of work or school.
If you are interested in becoming a FluWatcher, sign up today.
Figure 5 - Percentage of participants reporting fever and cough, Canada, weeks 2019-40 to 2020-05
Number of Participants Reporting in Week 05: 3,165
Figure 5 - Text equivalent
|Surveillance Week||% cough and fever|
Online Figure – Geographic distribution of FluWatchers participants reporting cough and fever, Canada, week 2020-05
Click on the map to access the link
Influenza Outbreak Surveillance
In week 05, a total of 28 outbreaks were reported: 14 in long term care facilities, 5 in acute care facilities, 5 in facilities categorized as ‘other’, which includes facilities such as private personal care homes, correctional facilities, and colleges/universities and 4 in schools and daycares (Figure 6). In addition, 43 ILI outbreaks in schools/daycares were reported.
To date this season, a total of 576 laboratory-confirmed influenza outbreaks have been reported; 61% (352) in long-term care facilities, 25% (144) in facilities categorized as ‘other’, 11% (64) in acute care facilities, and 3% (16) in schools/daycares. Of the 544 outbreaks where influenza type was reported, 90% (487) were due to influenza A. Among the 233 outbreaks for which the influenza A subtype was reported, 55% (127) were associated with A(H3N2). To date this season, 79 ILI outbreaks in schools/daycares have also been reported.
Figure 6 – Number of new outbreaks of laboratory-confirmed influenza by report week, Canada, weeks 2019-35 to 2020-05
Number of provinces and territories reporting in Week 05: 13 out of 13
Figure 6 - Text equivalent
|Surveillance Week||Acute Care Facilities||Long Term Care Facilities||Other||Schools and Daycares||Remote and/or Isolated Communities|
Severe Outcomes Influenza Surveillance
Provincial/Territorial Influenza Hospitalizations and Deaths
To date this season, 1,358 influenza-associated hospitalizations were reported by participating provinces and territories1.
- 65% of the cases were associated with influenza A.
- Of the 661 cases for which subtype was reported, 67% were associated with influenza A(H3N2).
- The highest cumulative hospitalization rates up to week 05 were among children under 5 years of age and adults 65 years of age and older (44/100,000 population).
129 ICU admissions and 38 deaths have been reported.
- 58% of the ICU admissions and 76% of the deaths were associated with influenza A.
Figure 7 – Cumulative rates of influenza-associated hospitalizations by age-group and surveillance week, Canada, participating provinces and territoriesFootnote 1 weeks 2019-35 to 2020-05
Number of provinces and territories reporting in Week 05: 8 out of 9
- Footnote ‡
Influenza-associated hospitalizations are reported by Alberta, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Prince Edward Island and Yukon. Only hospitalizations that require intensive medical care are reported by Saskatchewan.
Figure 7 - Text equivalent
|Surveillance Week||0-4 yrs||5-19 yrs||20-44 yrs||45-64 yrs||65+ yrs|
Pediatric Influenza Hospitalizations and Deaths
In week 05, 117 pediatric (≤16 years of age) laboratory-confirmed influenza-associated hospitalizations were reported by the Immunization Monitoring Program Active (IMPACT) network (Figure 8). The weekly number of cases increased compared to the previous week. The number of cases due to influenza B remains high; however, in recent weeks, a growing proportion of cases have been due to influenza A.
The elevated number of cases this season compared to previous seasons is likely due to the concurrent circulation of influenza A and B this season. The number of influenza A-associated pediatric hospitalizations is above the average for this time of year. The number of hospitalizations with influenza B is well above average compared to previous seasons, and occurring earlier in the season.
To date this season (weeks 35 to 05):
- 774 pediatric hospitalizations have been reported by the IMPACT network, of which 50% (389) were associated with influenza B and 50% (385) with influenza A.
- The largest proportion of hospitalizations (65%) were among children under 5 years of age (Figure 9).
- Among cases in children under 5 years of age (503), 56% were associated with influenza A, compared to cases in children 5 to 16 years of age (271), among whom 60% of cases were associated with influenza B.
- 114 ICU admissions were reported, of which 50% (46) were associated with influenza A.
- Less than five pediatric deaths have been reported.
Figure 8 – Number of pediatric (≤16 years of age) hospitalizations reported by the IMPACT network, by week, Canada, weeks 2019-35 to 2020-05
The shaded area represents the maximum and minimum number of cases reported by week from seasons 2014-15 to 2018-19
Figure 8 - Text equivalent
Figure 9 - Text Description
Adult Influenza Hospitalizations and Deaths
Surveillance of laboratory-confirmed influenza-associated adult (≥16 years of age) hospitalizations by the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network began on November 1st for the 2019-20 season. In week 05, the number of cases increased slightly, interrupting a recent declining trend.
To date this season, 474 hospitalizations, 33 intensive care unit admissions, and 14 deaths have been reported (Figure 10).
- The majority of hospitalizations have been due to influenza A (85%), and among those subtyped (112) 92% were influenza A(H1N1).
- Among cases with influenza A, the largest proportion of hospitalizations were in adults 65-79 years of age (32%) and adults 80 years of age and older (30%). Among the 72 cases with influenza B, 38% were between 16 and 34 years of age and 39% were 65 years of age and older (Figure 11).
- 73% of hospitalized cases reported at least one type of comorbid condition.
Figure 10 - Text Description
|Surveillance Week||Number of Hospitalizations|
Figure 11 - Text Description
|Age Group||Total hospitalizations|
Influenza Strain Characterizations
From September 1, 2019 to February 6, 2020, the National Microbiology Laboratory (NML) has characterized 555 influenza viruses (235 A(H1N1), 145 A(H3N2) and 175 influenza B) that were received from Canadian laboratories.
Over recent years, circulating strains of A(H3N2) have evolved, and are increasingly difficult to characterize by hemagglutination inhibition (HI) assay. Genetic characterization is established by sequencing the hemagglutinin (HA) gene of the influenza viruses to compare their genetic properties.
Among the 41 influenza A(H3N2) viruses antigenically characterized to date, the majority (85%) showed reduced titer by HI assay to A Kansas/14/2017 using antiserum raised against egg-propagated A Kansas/14/2017. Six viruses were characterized as A Kansas/14/2017-like (Figure 12 a).
Nearly all (98%) of the 135 A(H3N2) viruses genetically characterized this season belonged to genetic group 3C.2a1b based on sequence analysis of the HA gene. Three viruses belonged to the genetic group 3C.3a (Figure 13).
Group 3C.2a1b viruses analysed represent:
- 90% (28 out of 31) viruses that were also antigenically characterized.
- 100% (104 out of 104) viruses which did not grow to sufficient hemagglutination titer for antigenic characterization by HI assay.
A/Kansas/14/2017 belongs to genetic group 3C.3a and is the influenza A(H3N2) component of the 2019-20 Northern Hemisphere influenza vaccine.
Among the 235 A(H1N1) viruses characterized to date, 62% were antigenically similar to A/Brisbane/02/2018 by HI testing using antiserum raised against egg-propagated A/Brisbane/02/2018 (Figure 12 b).
A/Brisbane/02/2018 is the influenza A(H1N1) component of the 2019-20 Northern Hemisphere influenza vaccine.
Among the 175 influenza B viruses antigenically characterized this season, the vast majority (173) belonged to the B/Victoria lineage. Two viruses were antigenically characterized as similar to B/Phuket/3073/2013 (B/Yamagata lineage).
The majority (91%, 157) of B/Victoria lineage viruses showed reduced titer by HI assay to B/Colorado/06/2017 using antiserum raised against cell culture-propagated B/Colorado/06/2017 (Figure 12 c).
Sequence analysis of 105 B/Victoria lineage viruses with reduced titre to B/Colorado/06/2017 showed that 100% had a three amino acid deletion (162-164) in the HA gene. Sequencing is pending for the remaining viruses.
The recommended influenza B components for the 2019-20 Northern Hemisphere influenza vaccine are B/Colorado/06/2017 (Victoria lineage) and B/Phuket/3073/2013 (Yamagata lineage). B/Phuket/3073/2013 is included in the quadrivalent influenza vaccine.
Figure 12 - Text Description
|Number of viruses characterized: 41|
|Antigenic phenotype of A(H3N2) virus||Number of viruses||Percentage|
|Reduced titer to A/Kansas/14/2017||35||85%|
|Number of viruses characterized: 235|
|Antigenic phenotype of A(H1N1) virus||Number of viruses||Percentage|
|Reduced titer to A/Brisbane/02/2018||90||38%|
|Number of viruses characterized: 175|
|Antigenic phenotype of influenza B virus||Number of viruses||Percentage|
|Reduced titer to B/Colorado/06/2017||157||90%|
Figure 13 - Text Description
|Number of viruses sequenced: 135|
|Genetic Clade of A(H3N2) virus||Number of viruses||Percentage|
The National Microbiology Laboratory (NML) also tests influenza viruses received from Canadian laboratories for antiviral resistance. From September 1, 2019 to February 6, 2020, the following results were reported:
371 influenza viruses (132 A(H3N2), 117 A(H1N1) and 122 B) were tested for resistance to oseltamivir:
- All influenza A(H3N2) and B viruses were sensitive to oseltamivir.
- Among the A(H1N1) viruses tested, 116 (99%) were sensitive to oseltamivir and one virus was resistant to oseltamivir with the H275Y mutation in the neuraminidase gene.
371 influenza viruses (132 A(H3N2), 117 A(H1N1) and 122 B) were tested for resistance to zanamivir:
- All influenza viruses tested were sensitive to zanamivir.
High levels of resistance to amantadine persist among influenza A(H1N1) and influenza A(H3N2) viruses. All viruses tested this season were resistant.
Vaccine monitoring refers to activities related to the monitoring of influenza vaccine coverage and effectiveness.
Influenza vaccine coverage estimates for the 2019-20 season are anticipated to be available in February or March 2020.
Influenza vaccine effectiveness estimates for the 2019-20 season are anticipated to be available in February or March 2020.
Report a problem or mistake on this page
- Date modified: